PD-L1 & ALK Positive Control for IHC
Image courtesy of Dr. Till Braunschweig, M. D., Institute of Pathology, Universitätsklinikum Aachen, Germany.
PD-L1 (Programmed Cell Ligand 1, also known as CD274) is a receptor ligand which is expressed by hematopoietic and non-hematopoietic cells, such as T- and B-lymphocytes and various types of tumor cells. PD-L1 is a type-I transmembrane protein. Binding of PD-L1 to its receptor PD1 inhibits T-cell activation and cytokine production. This mechanism renders PD-L1 overexpressing tumor cells resistant to T cell-mediated lysis.Immunohistochemical detection of the PD-L1 protein is of great importance for the use of novel anticancer drugs such as checkpoint inhibitors.
Clone: BSR1 1 ml
Clone: BSR1 0.1 ml
Cell Control Block ALK stained with ALK clone 1A4 at a dilution of 1:200 with pre-treatment in EDTA, pH 9.0. ALK positive to the right, and ALK negative to the left.
ALK positive control for IHC
The Cell Control Array ALK (IHC) is a homogenous paraffin block including one ALK positive, one ALK negative cell line and two cores of muscle tissue. The block serves as a general control for the detection of ALK protein. ALK antibodies lead to staining in immunohistochemistry with the ALK positive cell line. ALK immunohistochemistry is often done as pre-screening on non small cell lung cancer. ALK positive cases are retested with FISH for ALK/EML4 gene rearrangement. Only patients with ALK/EML4 rearrangement are allowed to be treated with Crizotinib, a tyrosine kinase inhibitor that target ALK. Since only 3-5% of all NSCLC are positive for ALK, there is a high demand for a reliable positive control. ALK positive anaplastic large cell lymphoma (ALCL) should not be used as a positive control as its high ALK protein expression could lead to false negative results comparing to lowexpressing NSCLC. The cell line does not contain an ALK/EML4 gene rearrangement and is therefore not suited for in situ-hybridisation.
|Cell Control Array ALK (IHC)||1 Block||TCB-10105||RUO|